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Colorectal cancer (CRC) is one of the alarming and common health problem worldwide (1).  It is 
the third most commonly diagnosed cancer in males and the second in females(1,2) with an 
incidence rate of 9.4% in men and 10.1% in women, worldwide (3). In general, colorectal cancer is 
a disease of the elderly, but there is an increase in incidence among the younger individuals due to 
many dietary and environmental changes (4, 5). There are many prognostic factors described in the 
literature but in practice, none of them have been proved to be of definite significance. The stage of 
the disease is considered as one of the most significant prognostic factors.  
Few studies highlight that CDX2 immunohistochemistry negativity is an independent prognostic 
factor and indicates worse survival rate (6). The treatment for colorectal cancer is multidisciplinary 
which includes surgery, chemotherapy and radiotherapy. The treatment modality is also based on 
molecular studies in familial cases.  Prognostic biomarkers are key to the risk stratification of 
patients with colon cancer and the decision to recommend adjuvant chemotherapy, especially in 
patients with early-stage disease. Currently, tumor stage, tumor grade, and microsatellite instability 
remain the most important prognostic variables that aid in treatment of patients with early-stage 
colon cancer. Microarray-derived gene-expression signatures from stem cells and progenitor cells 
play a significant role but are difficult to translate into clinical tests. Hence, it has proved difficult 
to identify a single prognostic biomarker that is also predictive of benefit from adjuvant 
chemotherapy.  Few western studies have proved that CDX2-negative tumors are associated with a 
lower rate of disease-free survival than CDX2-positive tumor. This effect was independent of 
many known risk factors, including pathological grade and stage. In Indian literature, very few 
studies have been done on CDX2 expression and its correlation with clinicopathological and 
prognostic significance of colon cancer. This study aims to look at the prevalence of CDX2 
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immunohistochemistry expression in colon cancer and its correlation with clinicopathological 
parameters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
 
 
 
 
 
 
 
                                AIM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
 
 
 
 
 
1) To study the prevalence of CDX2 expression by immunohistochemistry in patients 
diagnosed as primary colonic adenocarcinoma in our hospital from January 2015 to June 2018. 
 
2) To correlate the expression of CDX2 immunohistochemistry in primary colonic 
adenocarcinoma with classification, anatomical site, differentiation, and TNM staging. 
 
3) To study the clinicopathological features of primary colonic adenocarcinoma.  
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1) To identify the total number of primary colon cancers in our institution during the period 
January 2015 to June 2018 from the electronic database. 
 
2) To do a detailed clinicopathological study of all the retrieved cases. 
 
 
 
3)  To assess the expression of CDX2 in endoscopic mucosal biopsies of all cases and to 
correlate it with clinical and histological parameters in the corresponding resection specimens. 
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EPIDEMIOLOGY 
 
 
             Colorectal cancer (CRC) is a formidable health problem worldwide and is one of common 
cancer worldwide. It constitutes 9.67% of the overall 14.1 million new cancer cases globally (1).  It 
is the third most commonly diagnosed cancer in males and the second in females(1,2). The 
incidence rate of CRC is 9.4% in men and 10.1% in women, worldwide(3). There is variation in 
incidence rates in different parts of the world and more than half of the cases of CRC and 63% of 
newly diagnosed CRC cases are reported from developed countries (1). CRC incidence and 
mortality rates vary markedly across the globe with regional differences. In the western population, 
colorectal cancer is one of the commonest malignancy, but in the East, cancers of the upper 
gastrointestinal tract (esophagus and stomach) and liver are predominant (4).  There is a rapid 
increase in the incidence of colorectal cancer in more developed and westernized Asian countries 
and there is a shift in trend from older to younger age group (5).  The incidence rates range from 
more than 40 per 100,000 people in the United States, Australia, New Zealand, and Western 
Europe to less than 5 per 100,000 in Africa and some parts of Asia (2).   
Worldwide, annually it is about 394,000 deaths from colorectal, amounting to the fourth most 
common cause of death from cancer (2).   But mortality rates are high in the undeveloped and 
developing countries because of limited resources and healthcare infrastructure. In Western 
countries, the mortality rates are decreasing due to early detection by screening and improved 
treatment of colorectal malignancy(6). The mortality rates are on the rise in Asian continent 
according to the WHO Mortality Database. There is the difference in incidences of colorectal 
cancer in many different ethnic groups in Asia (4).  
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Carcinoma colon is a relatively uncommon malignancy in India when compared with the western 
world. Indian and Malay populations have significantly lower incidences of colorectal cancer when 
compared with the Chinese population in Singapore and Malaysia. This difference in the incidence 
of colorectal cancer among races indicates genetic factors which play an important etiological role. 
There are conflicting results in Asian migrants to western countries. There is a significant increase 
in the incidence rate of colorectal cancer which is nine times higher among Asian Indian migrants 
to the USA. These observations suggest that genetic predisposition interacts with lifestyle 
modification including diet and environmental factors. In many Asian countries, there is an 
apparent increase in proximal colorectal cancers than distal ones. An aging population and the 
wider availability of colonoscopy might partly explain this increase in the incidence of proximal 
colorectal cancers in Asian countries. (4). In India, there is a sharp rise in incidences of all cancer 
due to poor to moderate living standards and inadequate medical facilities. The incidence rate of 
colorectal cancer is on the rise after the age of 45 years, more common in males than females and 
about 90% of cases are found in population over the age of 50 years. In India, the annual incidence 
rate for colon cancer is 4.4 per 1, 00,000 and 3.9 per 1, 00,000 in men and women respectively. 
 
The colorectal cancer survival and prognosis is dependent mainly upon the stage of disease at the 
time of initial diagnosis. The survival rates range from a 90% 5-year survival rate for localized 
stage cancers, 70% for regional and 10% for distant metastatic cancer. In general, there is a higher 
survival chance for cancers diagnosed at the earlier stage. The survival rates have increased 
substantially since the 1960s due to progress in diagnostic and treatment services (3). 
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THE 2010 WHO CLASSIFICATION 
 
 
According to WHO (2010), CRC is defined as a malignant tumor arising from large bowel with 
invasion into submucosa through muscularis mucosa. The carcinoma is subclassified as below: 
1) Adenocarcinoma 
a) Cribriform-comedo type adenocarcinoma 
b) Medullary carcinoma 
c) Mucinous adenocarcinoma 
d) Serrated adenocarcinoma 
e) Signet ring adenocarcinoma 
2) Adenosquamous carcinoma 
3) Spindle cell carcinoma 
4) Squamous cell carcinoma 
5) Undifferentiated carcinoma 
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 EMBRYOLOGY AND ANATOMY 
 
The three germ layers in embryogenesis are ectoderm, mesoderm, and endoderm. The embryonic 
endoderm gives rise to intestinal epithelium during gastrulation. The endoderm undergoes 
extensive folding for the formation of the embryonic gut tube, following induction and molecular 
patterning. There are no well-known mechanisms that initiate and control epithelial reorganization 
and morphogenesis of villus, although crosstalk between the gut epithelium and the mesenchyme 
has been shown to provide both permissive and instructive cues to allow the normal development 
of the intestine. BMP, Hedgehog, PDGF, TGF-β, and Wnt signaling pathways are  known to 
involve in this epithelial-mesenchymal crosstalk (7) 
The large intestine is being anatomically divided into caecum with an appendix, ascending colon, 
transverse colon, descending colon, sigmoid colon and rectum. Except ascending and descending 
colon, others are considered as intraperitoneal (8).      
                  
Figure 1: Anatomical subsites of colon, 8th Edition, AJCC Staging Manual 
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ETIOLOGY 
 
There are several risk factors associated with the CRC incidence. Generally, risk factors are 
categorized into non-modifiable and modifiable or environmental factors.  
NON MODIFIABLE RISK FACTORS: 
 
1) AGE – Incidence of CRC increases with age. About 90% of colorectal cancer cases are seen 
in people aged 50 or older. The incidence rate in persons aged 60 to 79 years is more than 
50 times higher than in those younger individuals. CRC incidence is rare in an age less than 
40 years, except in those with a genetic predisposition or predisposing conditions such as 
chronic inflammatory bowel disease. However, colorectal cancer appears to be increasing 
among younger person (2,9,10).  
 
2) ADENOMATOUS POLYPS - The precursor lesions of colorectal cancer are mainly 
neoplastic polyps, namely tubular, tubulovillous and villous adenomas. About 95% of 
sporadic colorectal cancers arise from these adenomas. There is increased risk noted for 
hyperplastic and adenomatous polyps which transform to carcinoma. There is a long latency 
period, about 5 to 10 years, is required for the development of cancer from adenomas. There 
is a 20% higher relative risk of developing colorectal cancer in people who have a family 
history of the adenomatous polyp, especially in the first-degree relatives (2,9,11) 
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3) INFLAMMATORY BOWEL DISEASE - Ulcerative colitis and Crohn disease are the two 
disease included in inflammatory bowel disease. Ulcerative colitis causes inflammation of 
the mucosa of the colon and rectum, whereas, Crohn disease can involve any part of the 
digestive tract from the mouth to the anus and causes full thickness inflammation of bowel 
wall. It has been estimated that the relative risk is between 4- to 20-fold in patients with 
inflammatory bowel disease. Schistosoma mansoni infection also aids in the development of 
CRC. (2, 11–13) 
 
4) GENETIC RISK - Approximately 5 to 10% of colorectal cancers are the result of 
recognized hereditary conditions. Familial adenomatous polyposis (FAP) and hereditary 
nonpolyposis colorectal cancer (HNPCC), also called Lynch syndrome is the most common 
inherited conditions. HNPCC attribute 2 to 6% of colorectal cancers, whereas, FAP 
accounts for less than 1% of all colorectal cancer cases. The lifetime risk of colorectal 
cancer in people is approximately 70% to 80% with the known HNPCC-related 
mutations and the average age at colorectal cancer diagnosis is in their mid-40s but in FAP, 
malignant transformation of adenomas occurs as early as age 20. By age 40, almost all 
people with FAP will have developed cancer if the colon is not removed. 
 
MODIFIABLE OR ENVIRONMENTAL FACTORS: 
It broadly includes a wide range of often ill-defined factors including cultural, social and lifestyle 
factors. Part of evidence of environmental risk comes from studies on the migrants and their 
offspring. There are some other geographic factors which influencing differences in the incidence 
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of colorectal cancer, apart from migration, one of them is an increase in the incidence among urban 
residents. 
 
1) DIETARY FACTORS - Diet has a strong and direct influence on the risk of colorectal 
cancer. Approximately 70% reduction is seen if there are changes in food habits. Diets 
especially high in fat, are considered as one of the major risk factors for colorectal cancer.  
The fatty diet favors the development of a bacterial flora which is capable of degrading bile 
salts to N-nitroso compounds which are potent carcinogens. High meat consumption has 
also been proved as one of the risk factors in the development of colorectal cancer. The 
meat consumption causes colon cancer more than rectal cancer. The underlying mechanisms 
are the production of heterocyclic amines and polycyclic aromatic hydrocarbons which have 
carcinogenic properties, which are formed while cooking red meat at high temperatures. 
Hence ‘western type diet’ (highly caloric food rich in animal fat) combined with a sedentary 
lifestyle shows an increase in CRC. In addition, a diet low in fruits, vegetables, whole 
grains, calcium, selenium and vitamin D have an increased risk of colorectal cancer (2,15–
17).  
 
2) PHYSICAL ACTIVITY AND OBESITY- About a fourth to a third of colorectal 
malignancy are related to excess body weight and physical inactivity. There are studies 
proving that frequency and intensity of physical activity inversely associated with risk of 
colorectal cancer. The risk of colorectal cancer can be reduced by a healthy diet and regular 
physical activity, although the evidence is stronger for colonic than for rectal disease. Due 
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to sustained physical activity increases oxygen uptake and raises the metabolic rate. Regular 
physical activity increases metabolic efficiency, reduces insulin resistance and blood 
pressure and also increase gut motility. The lack of physical activity leads to obesity in men 
and women which increases circulating estrogens and decreased insulin sensitivity, leading 
to increased cancer risk (2,18,19) 
 
3) CIGARETTE SMOKING- There is proven evidence between tobacco cigarette smoking 
and lung cancer. But smoking also is extremely harmful to the colon and rectum. There are 
studies revealing that smoking contributes 12% of colorectal cancer deaths. The carcinogens 
found in tobacco increases the cancer growth in the colon and rectum. The formation and 
growth rate of adenomatous polyps, precursor lesions of colorectal cancer increases due to 
cigarette smoking (2,20) 
 
4) ALCOHOL CONSUMPTION- Regular alcohol consumption is associated with an 
increased risk of developing colorectal cancer like cigarette smoking. One of the factors 
leading to the development of colorectal at a younger age is consumption of alcohol on 
regular basis. The reactive metabolites of alcohol like acetaldehyde can be 
carcinogenic.  Alcohol also acts as a solvent for other carcinogenic molecules and 
enhancing the penetration of these molecules into mucosal cells. Also, there is the 
production of prostaglandins, lipid peroxidation and the generation of free radical oxygen 
species due to alcohol. Lastly, high alcohol consumers have diets low in essential nutrients, 
making tissues susceptible to carcinogenesis. (2,21) 
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CLINICAL FEATURES 
 
SIGNS AND SYMPTOMS 
The symptom for CRC varies according to the site, size, and extent of invasion. The common 
symptoms of colonic carcinoma include, 
- Abdominal pain  
- Bleeding per rectum 
- Alteration in bowel habits 
- Loss of weight and appetite 
- Intestinal obstruction 
- Perforation and peritonitis 
- Anemia 
 
The presenting symptoms vary according to the site whether it is a left-sided colon disease or a 
right-sided disease. For left side CRC, the most common symptoms include a change in bowel 
habit, either constipation or diarrhea. Generally, the left-sided colonic tumors proliferate in annular 
or constrictive fashion which leads to progressive narrowing of the bowel lumen. Moreover, the 
feces becomes less soft and gets impacted which leads to intestinal obstruction and perforation, 
especially seen in advanced cases. On the other hand, the right-sided colon cancer has a 
proliferative morphology which causes mild bleeding leading to iron deficiency anemia. Hence 
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urgent referral and evaluation are needed for iron deficiency in women who are not menstruating 
and men. Other non-specific symptoms include fever, malaise, weight loss and abdominal pain 
(22–24). 
  
IMAGING 
The imaging techniques which aid in the diagnosis of CRC include computer-assisted tomography 
(CT), magnetic resonance imaging, transrectal ultrasonography, and positron emission tomography 
(PET). These imaging methods are non-invasive and aid the clinician not only in detection but also 
in clinical staging. Barium studies are completely replaced by CT and CT colonography. 
Significances of transrectal ultrasonography help to estimate the depth of invasion and the 
possibility of regional and distant metastasis. PET scanning and scintigraphy is used to assess the 
spread of the diseases  (25–27) 
 
ENDOSCOPY 
Colonoscopy helps in direct visualization of the mucosal surface of the entire colon. In addition, 
biopsy or therapeutic removal of the identified lesion can be done by snare polypectomy, 
endoscopic mucosal resection for adenomas and superficial carcinoma. Use of chromoendoscopy 
employing dyes and confocal endoscopy aids in better visualization (26,28) 
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PATHOLOGY 
 
With the rapid advancement in therapeutic intervention, the role of pathologists is inevitable in 
diagnoses and in the management of patients with CRC. The pathologists are responsible, not only 
for exact histopathological diagnosis but also in assessing pathologic staging, searching for 
prognostic parameters that are not included in the staging including lymphovascular and perineural 
invasion, analyzing surgical margins and assessing the therapeutic effect of adjuvant therapy in 
patients. 
 
 Histologically, the colorectal carcinomas predominantly comprise adenocarcinomas (90%) 
originating from epithelial cells of the intestinal mucosa. The characteristic features of 
adenocarcinoma are the glandular formation and are the basis for histologic tumor grading. If the 
tumor has >95% of glandular differentiation, then they are grouped as well differentiated 
adenocarcinoma.  If the tumor displays 50-95% gland formation, they are grouped as moderately 
differentiated adenocarcinoma. If the tumor is predominantly solid in nature with <50% of gland 
formation, then they are grouped under poorly differentiated adenocarcinoma. The tumor grade is 
considered as a stage-independent prognostic variable, and poorly differentiated or high-grade 
histology is associated with poor patient survival (29,30).  
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HISTOLOGICAL VARIANTS (29) 
 In World Health Organization (WHO) classification, the common histologic variants of CRC are 
mucinous, medullary, signet ring cell, micropapillary, cribriform comedo-type, serrated, spindle 
cell, adenosquamous and undifferentiated. Other rare variants included are clear cell carcinoma 
and Paneth cell rich papillary adenocarcinoma. 
Mucinous adenocarcinoma. 
Adenocarcinoma with >50% of extracellular pools of mucin that contains malignant cells in acinar 
structure or individual cells including signet ring cells. Majority of mucinous adenocarcinomas are 
MSI-H and hence low-grade tumors. Mucinous adenocarcinoma with MSS and MSI-L behave as 
high-grade tumor(29,31) 
                         
                                             Figure 2: Mucinous adenocarcinoma (30) 
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Signet ring cell carcinoma 
Tumors are designated as signet ring cell carcinoma by the presences of >50% of tumor cells with 
predominant intracytoplasmic mucin with molding and displacement of the nucleus. Large signet 
ring cells are known as ‘globoid cells’. This is considered to be a very aggressive variant (29,32).  
 
                
                                                                  Figure 3: Signet ring cell carcinoma (30) 
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Medullary carcinoma 
These tumors are not generally common and are characterized by sheets of malignant cells with 
vesicular nuclei, prominent nucleoli and abundant eosinophilic cytoplasm with prominent 
intraepithelial lymphocytic infiltration. Tumors are MSI-H and usually have favorable prognosis 
(29,33) 
 
          
                                             Figure 4: Medullary carcinoma (30) 
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Serrated adenocarcinoma 
This tumor has an architectural similarity to a sessile polyp with glandular serration and low 
nucleus to cytoplasmic ratio. Three major patterns associated with these tumors namely serrated 
pattern, trabecular pattern and mucinous pattern. These tumors can be MSI-L,   MSI-H, and can be 
associated with BRAF mutation and CpG island hypermethylation (34,35).  
     
           
                                        Figure 5: Serrated adenocarcinoma (30) 
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Cribriform comedo-type adenocarcinoma. 
These rare tumors exhibit extensive large cribriform glands with central necrosis, which are 
usually microsatellite stable and show CpG island hypermethylation. They appear analogous to 
breast adenocarcinoma (36). 
 
         
                                  Figure 6: Cribriform comedo-type adenocarcinoma (30) 
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Micropapillary adenocarcinoma. 
This variant appears as small clusters of tumor cells within stromal spaces mimicking vascular 
channels. This component is seen along with conventional adenocarcinoma. Characteristic MUC1 
immunostaining is present in these tumors (37–39). 
        
        
                                         Figure 7: Micropapillary adenocarcinoma (30) 
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Spindle cell carcinoma 
These are biphasic tumors with a spindle cell sarcomatoid component which is focally 
immunoreactive for keratins (40,41). 
 
Adenosquamous carcinoma 
These tumors are rare and show features of adenocarcinoma and squamous cell carcinoma, either 
mixed or separate areas in the same tumor (30). 
 
Undifferentiated carcinoma. 
These are rare tumors which lack morphological, immunohistochemical and molecular biological 
evidence of differentiation beyond that of epithelial tumors. Some of these tumors are MSI-H (30). 
 
GRADING 
Generally, colorectal carcinoma is graded as well-, moderately, poorly and undifferentiated 
adenocarcinoma on the basis of percentage of the glandular formation. Undifferentiated carcinoma 
is designated for malignant tumors with no glandular formation, mucin production, 
neuroendocrine, squamous or sarcomatoid differentiation. Clinically, the tumors are classified as 
high grade and low grade. Other morphological variants are not graded because of their own 
prognostic significance. If the tumors are heterogeneous, grading depends upon the least 
differentiated component (29,34,42,43).   
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    Grade 1 – well differentiated (>95% gland formation) 
    Grade 2 – moderately differentiated (50-95% gland formation) 
    Grade 3 – Poorly differentiated (<50% gland formation) 
    Grade 4 – Undifferentiated (no gland formation or mucin, no squamous or  
                                                                              Neuroendocrine differentiation) 
 
PATHOLOGY STAGE (AJCC Staging Manual, 8th Edition) 
 
 
27 
 
 
 
 
           
                                                           Figure 8: Stages of colon cancer 
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PRECURSOR LESIONS 
 
Aberrant crypt foci (ACF) 
ACF are abnormal crypt clusters seen on staining colorectal mucosa with methylene blue or 
chromoendoscopy. There are two main types: those which resembles hyperplastic polyps 
(common) and others with dysplasia (rare). Increased numbers of ACF has a close association with 
neoplasia. 
 
Adenomas 
According to WHO (2010) adenomas are defined by the presence of dysplastic epithelium. 
Enlarged, hyperchromatic nuclei, varying degree of nuclear spindling and stratification and loss of 
polarity are considered as features of dysplasia. Depending upon architectural complexity, the 
extent of nuclear stratification and pleomorphism, dysplasia can be grouped into the low and high 
grade. Grossly these adenomas are polypoidal, either sessile or pedunculated. A few ones have flat 
or depressed surface. There are mainly three architectural patterns, tubular, villous and 
tubulovillous types. Clinical significance of adenomas is their association with occurrence of 
synchronous and metachronous carcinoma. Adenomas of size larger than 1cm, extensive villous 
architecture, and high-grade dysplasia will be mostly associated with an invasive component or can 
transform into malignancy (44–46). 
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Serrated lesions 
A heterogenous group of lesions morphologically characterized by  serrated architecture in the 
epithelial component. They include hyperplastic polyp, sessile serrated adenoma/ polyp and 
traditional serrated adenomas (30) 
 
Juvenile polyp. 
Usually, juvenile polyps are seen in children. These lesions are characterized by abundant stroma 
composed of edematous, granulation tissue that surrounds cystically dilated glands containing 
mucin. Dysplasia is very uncommon in sporadic cases. In juvenile polyposis syndrome often have 
frond-like growth pattern with less stroma and many proliferated small glands, microtubular 
pattern and has increased the risk for dysplasia and malignant transformation (47,48).  
 
 Puetz- Jeghers polyp 
These are hamartomatous polyps arising in the gastrointestinal tract, mainly in the small intestine, 
along with mucocutaneous melanin pigmentation. These polyps are a component of Puetz-Jeghers 
syndrome (49). 
 
GENETIC SUSCEPTIBILITY 
CRC cases with familial clustering are approximately 10-35% in which only <6% have high-risk 
germline mutation which predisposes to CRC associated syndromes. Familial adenomatous 
polyposis and Lynch syndrome (non-polyposis) are considered as high-risk genetic diseases. 
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Majority of these syndromes are autosomal dominant except MUTYH- associated polyposis which 
is autosomal recessive (50,51).  
 
 
 
 
MOLECULAR PATHOLOGY 
 
There are distinct pathological features, molecular signatures and natural histories for colorectal 
cancer and its precursors. There are mainly three pathway discovered which includes chromosomal 
instability (CIN), microsatellite instability (MIS) and CpG island methylator phenotype (CIMP) 
pathway. The predominant pathway (~ 85%) is contributed by the CIN pathway. Due to the 
understanding of the molecular pathology underlying colorectal carcinogenesis, a multi-tier 
approach is implemented for reducing the burden of CRC through earlier diagnosis of cancer and 
the detection and removal of benign polyp precursors. Patients with a past history of colorectal 
neoplasia or symptomatic patient are subjected to colonoscopy for diagnosis and surveillance. 
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Patients with familial colorectal syndromes are identified and managed by combined endoscopic 
and molecular test. Genomic instability is critical in carcinogenesis which enhances the neoplastic 
evolutionary process. The development of new mutations would be too slow for a carcinogenesis 
without genomic instability. 
 
 THE CHROMOSOMAL INSTABILITY (CIN) PATHWAY 
 
About 70%-85% of colorectal cancers develop through the CIN pathway.  In the CIN pathway, 
significant molecular aberrations occur through the accumulation of structural or numerical 
chromosomal abnormalities. Dysplastic aberrant crypt focus is the earliest identifiable lesion in this 
pathway, which is a microscopic mucosal lesion that precedes the development of polyp. The CIN 
pathway and its accompanying adenoma-carcinoma sequence have laid a foundation for the 
molecular classification of colorectal carcinogenesis but it is now proven that colorectal cancer can 
also develop by other pathways. 
The mutation associated with the CIN pathway include APC gene, KRAS oncogene, loss of 
chromosome 18q and chromosome 17p deletion, which contains the tumor suppressor gene TP53 
(53–55) 
 
APC, important tumor suppressor gene, plays a vital role in the CIN pathway. Mutation in APC 
gene truncate APC protein and prevents binding of APC to β-catenin which releases the 
suppression Wnt-signaling pathway. The purpose of Wnt signaling is to regulate growth, apoptosis, 
and differentiation.  Loss of functional APC might also Influence the regulation of mitosis 
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contributing to CIN. APC mutation is seen in approximately 80% in early adenoma, 60% of 
colonic and 82% of rectal cancers. 
 
KRAS (12p12) is one of the other important gene involved in the CIN pathway. KRAS gene 
encodes a GTP-binding protein which, when mutated, can cause inherent GTPase activity loss and 
thus constitutive signaling through the RAS-RAF-MEK-ERK pathway. KRAS is not particular to 
the CIN pathway, but KRAS has a significant role in the CIMP pathway as well. About 35-42% of 
colorectal cancer and in a similar number of advanced adenomas reveals KRAS mutations.  
 
SMAD2 and SMAD4, located at18q21.1, are involved in the TGF-β signaling pathway, which 
regulates growth as well as apoptosis. About 60% of colorectal cancer is associated with allelic 
loss of these genes. Generalized juvenile polyposis syndrome due to germline mutation of SMAD4 
can cause colorectal cancer. 
 
Lastly, impairment of TP53 (17p13) by the allelic loss of 17p is usually a late event in the 
traditional pathway, from adenoma to adenocarcinoma. Either mutation or loss of heterozygosity 
causes TP53 abnormalities which leads to the advancing histological stage of the lesion. About 
50% of adenomas with invasive foci and 50-75% of colorectal cancer have impaired function of 
TP53.  The p53, guardian of the cell cycle, increase the expression of cell-cycle genes and slow 
down the cell cycle, providing sufficient time for DNA repair. The p53 protein induces pro-
apoptotic genes if the genetic damage is too high (52,53,56,57) 
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MICROSATELLITE INSTABILITY (MSI) PATHWAY  
 
Microsatellites are certain nucleotide repeat sequences which are seen scattered throughout the 
genome. The discrepancy in the nucleotide repeat numbers found within these regions in tumor 
leading to microsatellite instability. Mismatch repair (MMR) dysfunction is caused when copying 
these repeat sequences by DNA polymerase enzyme, resulting in MSI. MMR system is composed 
of seven proteins, at least, including, MSH2, MSH3, MLH1, MLH3, MSH6, PMS1, and PMS2. 
MSH2 and MLH1 are main in the mismatch repair machinery and these form five functional 
heterodimeric proteins (MSH2-MSH6, MSH2-MSH3, MLH1-PMS1; MLH1-MLH3, MLH1-
PMS2). In HNPCC, mutations in MLH1, MSH2, MSH6, and PMS2, have been seen. MSI-high 
(MSI-H) or considerable MSI is when MSI ≥2 (40%) of the five specified sites, MSI low (MSI-l), 
when MSI at one site, whereas microsatellite stable (MSS) when no instability is seen at these sites 
(52,57–59). 
 
CpG ISLAND METHYLATOR PHENOTYPE PATHWAY (CIMP) 
 
The second most common pathway to sporadic CRCs (15%). CIMP pathway leads to epigenetic 
instability by methylating the promoter regions of tumor suppressor genes such as MLH1 and thus 
epigenetically inactivate expression of these genes. Currently, colorectal cancers with CIMP-
positivity are defined by a panel of CpG island methylation marker that are classified on the basis 
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of stipulated thresholds to tumors having DNA methylation or not. There is no Gold-standard 
technique for methylation categorization for diagnosing CIMP. The recommended panel is of five 
markers including CACNA1G, IGF2, NEUROG1, RUNX3, and SOCS1. CIMP-positive tumors 
show predominantly cancers with a percent of methylated reference (PMR) of ≥10 at three or more 
gene promoter sites are categorized as CIMP positive. These tumors show association with BRAF 
and KRAS mutation. Few authors classify CIMP-positive group into CIMP low (or CIMP2) and 
CIMP-high (or CIMP1) group. CIMP2 colorectal tumors show a closer association with KRAS 
rather than BRAF mutation (52,57) 
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Studies on molecular pathology including CIN, MSI, and CIMP which often overlap in molecular 
tumor subtypes, has significant effects on prognosis. Initially, the tumors were categorized as MSI 
or MSS tumors. The MSS subgroup was further classified as CIN-only, CIMP-only, CIN+CIMP, 
and triple negatives ones. The MSI tumors show the lowest frequency for KRAS and APC mutations, 
the second lowest for p53 mutations, and the highest for BRAF V600E mutations. The CIN-only 
tumors exhibited the lowest frequency for BRAF V600E mutations and the highest 
for p53 mutations. These molecular subtypes based on MSI, CIMP, BRAF-mutation, and KRAS-
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mutation status has a close association with patient survival outcome. The highest five-year disease 
specific survival (89.5%) is for the MSI-H tumors, followed by the MSI-L/MSS tumors (82.5%) 
without CIMP or  KRAS and BRAF mutations, and the tumors with KRAS mutations (72.4%) only. 
The worst survival (49.2%) is for the tumors with CIMP and BRAF mutations. CIMP associated 
tumors have poor disease-free survival and overall survival rate irrespective of the MSI status. 
 The clinical significance of classifying tumors according to mutations are essential in determining 
the treatment regimen. The main line for treatment is the combination of 5-fluorouracil (5-FU) or 
capecitabine along with oxaliplatin or irinotecan. Targeted therapies for epidermal growth factor 
(EGFR) and vascular endothelial growth factor (VEGF) inhibitors have been found effective as 
both first and second line for CRC treatment. Studies suggest that anti-EGFR treatment is 
ineffective in tumors with codon 12 and 13 mutations in KRAS. Henceforth, anti-EGFR inhibitors 
are considered as contraindicated in those patients with mutant KRAS. The BRAFV600E mutation 
has poor disease-specific survival, which has resistance to anti-EGFR therapies even in the wild-
type KRAS tumors (34,52,53,57,58,60) 
 
PROGNOSTIC FACTORS 
 
There are many prognostic factors which indicate a high risk for progression, recurrence, and 
resistance to therapy. Some of the significant prognostic markers are described below. 
TUMOR MORPHOLOGY. 
  Tumor size- The tumor size has a direct association with the prognosis of CRC. Some studies 
indicate that if the primary tumor size is equal or more than 6.5 cm (≥ 6.5cm) is considered as bad 
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prognostic factor. Tumor size is considered a strong and independent risk factor in metachronous 
tumors. Large colonic tumors are generally associated with microsatellite instability (MSI).  But 
tumor size has less significance when compared to the tumor stage (61)  
  Tumor budding- Studies have shown that tumor budding is considered as one of the strong 
adverse prognostic factors in colorectal cancer. Generally, tumor budding is a morphologic 
phenomenon seen at the invasive tumor front. It is characterized by isolated or small clusters of 
tumor cells (<5 cells) which separated from the main tumor and migrate into desmoplastic stroma 
for a short distance. It represents localized tumor dedifferentiation which is recognized as a 
significant component in the metastatic process.  
   Tumor grade – Poorly differentiated and undifferentiated (grade 4) tumors are considered as 
important prognostic factors. Usually, these tumors have an aggressive behavior and have an 
increased chance for recurrence and metastasis. Poorly differentiated clusters (PDC) are defined as 
clusters containing more than or equal to five cancer cells (≥5 cells) present at tumor invasive front 
without any glandular differentiation. PDC is considered an evolution of tumor bud. They are 
strongly associated with lymphovascular invasion and lymph node metastasis. Histological variants 
like signet ring cell carcinoma, mucinous adenocarcinoma (in absence of MSI-H), small cell 
carcinoma and adenosquamous carcinoma have a poorer prognosis. Medullary-type associated 
with diploid status, MSI-H has reduced nodal involvement and has improved survival  (55,62,63).  
  Tumor stage – AJCC tumor node metastasis (TNM) stage remains the gold standard of prognostic 
factors in colorectal cancer. Initially, the TNM staging system was implemented to predict the 
prognosis of the disease, but now, they aid in planning treatment protocols also. For stage III 
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disease adjuvant therapy is accepted but for stage II tumors adjuvant therapy is not yet 
recommended as a treatment protocol.(23, 34, 52, 55)  
  Lymphovascular and perineural invasion – These parameters are significant prognostic factors. 
Extramural venous and lymphatic invasion leads to the formation of micro-metastases and causes 
metastatic tumor deposits. They also indicate a higher risk of regional recurrence after surgical 
resection and nodal involvement. They are also associated with decreased overall survival in 
metastatic disease (63,65) 
  Lymph node involvement – This indicates tumor metastasis, upgrades stage of the tumor and 
renders a bad prognosis. They also play an important role in deciding treatment protocol, 
particularly adjuvant chemotherapy. Patients with node-negative disease have a better 5-year 
survival rate of 70%-80%. Hence obtaining adequate numbers of lymph nodes is considered a 
crucial role for accurate staging(63,66). 
  Tumor-infiltrating lymphocytes – There is an improvement of overall and disease-specific 
survival rate if the tumor and peritumoral stroma are infiltrated by many CD3 and CD8 T cells 
(63).   
Other potential predictors are extend of resection, margin involvement, bowel obstruction or 
perforation, age older than 70 years, preoperative and postoperative serum carcinoembryonic 
antigen (CEA) levels, preoperative carbohydrate antigen 19-9 (CA19-9) levels, tumor location and 
infiltrative growth pattern (64,67,68). 
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PROGNOSTIC AND PREDICTIVE GENES  
 
Many studies suggest molecular or immunohistochemical prognostic markers for CRC but none of 
them are adopted into routine practice. The lack of marker utility is due to the complexity of CRC 
with molecular subgroups which have different biological behavior but often shares markers. At 
present, mutations involving BRAF, PIK3CA, allelic imbalance at 18q and overexpression of 
osteopontin, CXCL12 and CD133 has a poorer prognosis (69–71). 
Predictive gene and biomarkers indicate the likelihood of tumor resistance or response to therapies. 
Hence specific targeted chemotherapeutic agents can be used for the therapy. Most of CRC express 
EGFR on the cell surface, hence use of anti-EGFR (cetuximab & panitumumab) are effective for a 
treatment regimen. However, EGFR signals work through RAS/RAF pathway. Hence, if there is a 
mutation in the downstream KRAS, the tumors will be unresponsive for the anti-EGFR therapy. 
Therefore, testing for KRAS mutation (codon 12/13, 61 & 146) is essential for CRC therapy.  
Mutation of PIK3CA and loss of PTEN also are adverse predictive markers. Expression of epi- and 
amphiregulin ligands and EGFR amplification are favorable predictive markers. MSI-H has a poor 
response to 5-fluorouracil and oxaliplatin. In the absence of mismatch repair mechanism, 
administration of these agents do not cause apoptosis and causes resistance. Administration of 
irinotecan has a favorable outcome in MSI-H tumors. Hence detection of these predictive genes is 
now becoming an inevitable part of the treatment of CRC (56,58,60,72). 
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CAUDAL-TYPE HOMEOBOX TRANSCRIPTION FACTOR 2 (CDX2). 
 
The human Cdx1 and Cdx2 genes are mammalian homologs of Drosophila homeobox-containing 
gene Caudal  (73) located in chromosomes 13q12-13 (74). These genes encode transcription 
factors which are expressed largely restricted to the epithelium of the gut mainly throughout the 
small and large intestine. Studies also reported that Cdx1 gene expression exhibit a gradient, the 
highest level caudally, whereas Cdx2 expression is maximum at proximal colon and reduces 
caudally. Cdx genes play an important role in epithelial positional along the rostral-caudal axis of 
the gastrointestinal tract. Many in vitro studies have shown that CDX2 overexpression in gut 
epithelial cells results in growth arrest along with upregulation of several genes associated with 
differentiation of intestinal epithelium (73–75). Intestinal differentiation by CDX2 is by activating 
transcription of intestine-specific proteins, like MUC2, isomaltase, carbonic anhydrase I and 
sucrose (74,75). The current paradigm is that Cdx2 Is considered as a master “control gene” 
regarding intestinal epithelial differentiation (75).  In rat and mice, disease models exhibit decrease 
In Cdx2 expression as the tumor upgrades in humans, that is when the tumor grade increases 
expression of Cdx2 decreases (73,74). Hence, there is an inverse correlation between tumor grade 
to CDX2 staining (74). High-grade adenomas display reduced CDX2 expression when compared 
with low-grade adenomas or even normal tissue. This reduction is not completely attributed to 
mutation of the Cdx alleles but small deletions within both Cdx2 alleles is noted in replication error 
human colorectal cancer (73). Hamartomatous polyps arise when there is one copy of the Cdx2 
gene is eliminated in mice  (75), hence proving tumor suppressor quality of this gene (76). Poorly 
differentiated colon cancer has a higher proportion of CDX2-negative cases than differentiated 
41 
 
counterparts.  The CDX2 expression is graded according to the percentage of positive cells as 
0(negative), 1+ (<25%), 2+ (25-75%) and 3+ (>75%) (76). 
There is an association with lymph node metastasis. In invasive front of carcinoma, if CDX2 is 
negative leads to transient tumor cell differentiation defect that triggers dissemination of tumor 
cells through the blood and lymphatic vessels. Therefore, CDX2 plays a pivotal role in adenoma 
growth and malignant transformation and also the progression of colorectal cancer (74). High 
levels of CDX2 is also seen in neuroendocrine tumors derived from intestinal epithelium, hence 
these also play an important role in normal neuroendocrine cell differentiation. Other than 
intestinal adenocarcinomas, CDX2 nuclear staining is also seen in gastroesophageal 
adenocarcinomas (20%), ovarian adenocarcinomas and uterine endometriosis (20% & 4.3%), 
mucinous adenocarcinomas (20%) and prostatic adenocarcinoma (1%). Other significant uses of 
CDX2 staining are in the workup of metastatic tumors at other sites and aids in well-differentiated 
neuroendocrine tumor differential diagnosis (75).   
 
Regarding the prognosis of CRC, CDX2 negative tumors are associated with bad prognosis with 
regards to five-year disease-free survival period.  For CDX2 negative tumors have a lower rate of 
survival regardless of low or high pathological grade. Some studies have shown that stage II CDX2 
negative tumors have a lower rate of five-year disease-free survival than stage II CDX2-positive 
tumors with respect to overall survival. CDX2 status not only aids in assessing the prognosis but 
also helps in planning treatment regimens. Few studies reveal a higher rate of disease-free survival 
for CDX2 negative tumors with adjuvant chemotherapy in stage 2 CRC (77).  Prognostic 
biomarkers are those parameters which aid in risk stratification and in decision to recommend 
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adjuvant chemotherapy.  At present, tumor grade, tumor stage, lymphovascular and perineural 
invasion, lymph node metastasis and microsatellite instability are significant prognostic variables 
in CRC for development of treatment algorithms. Previous studies had shown that CDX2 negative 
tumors are associated with several adverse prognostic variables like an advanced stage, poor 
differentiation, vascular invasion, BRAF mutation, and CIMP-positive status.  Hence CDX2 is 
considered as an independent prognostic factor in CRC (77). 
 
TREATMENT 
 
The medical treatment of colorectal cancer was not well defined with little or no progress until the 
early 1990s. The establishment of effective adjuvant chemotherapy and the treatment of advanced 
cancer has improved gradually since then. Over the past few years, colorectal cancer has had many 
new developments in adjuvant chemotherapy. Most of these new treatments are still undergoing 
phase III trials and have not yet been included in the standard protocol for treatment. However, if 
these therapies are proved effective, they will open a new door for cancer treatment in the future 
(78). 
 
Currently, the treatment protocol is dependent on the stage of the disease and the main goal is to 
remove the tumor with adequate clearance.  Surgery is the primary treatment modality by which 
this is achieved. The usual surgical approaches for colon carcinoma include total, partial, or 
segmental colonic resection. Generally speaking, Stage 0 & I tumors require only resection and no 
further adjuvant therapy. 
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Stage 0: 
In stage 0 CRC, the tumor is limited to the colon wall and the main aim is to remove the tumor 
with adequate margin. If the tumor is polypoid and small in size, the mode of surgery implemented 
is polypectomy, usually done endoscopically. If the tumor is larger, removing a segment of the 
colon (fractional colectomy) is required. There is no increased benefit to the administration of 
chemotherapeutic agents. On the other hand, these agents may cause other adverse effects to the 
patients. 
 
Stage I: 
Stage I colon disease refers to those tumors that have infiltrated into the colonic wall, up to the 
submucosa and have not spread outside the colon. The standard treatment is surgery by removing 
the affected segment of colon and neighboring lymph nodes. Adjuvant therapy is not 
recommended.  
 
Stage II: 
Stage II colon tumors may be of a larger size, but are still limited to the colonic serosa and have 
not yet spread to the regional lymph nodes. The mainstay of treatment is surgery, either segmental 
colectomy along with regional lymph node dissection (incomplete colectomy) or total colectomy. 
This decision is based on the size and location of the disease.  Lymph node dissection is considered 
adequate when a minimum of twelve lymph nodes is found.   
Adjuvant chemotherapy is needed if the tumor has a higher risk for local recurrence or metastasis. 
The increased risk is seen in tumors with a large size, lymphovascular invasion, perineural 
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invasion and those involving the serosa. A few studies have shown that CDX2 
immunohistochemistry negativity is an indication for adjuvant therapy. 
 
Stage III: 
Stage III colon tumors are those that have spread into the regional lymph nodes but had not yet 
metastasized. Surgery followed by adjuvant chemotherapy is the standard treatment for tumors of 
this stage. For adjuvant chemotherapy, either the 5-Fluorouracil, oxaliplatin or capecitabine 
regimens are utilized frequently. However, in recent days, chemotherapeutic agents are more often 
decided based on mutational studies. Radiation treatment and/or chemotherapy might be used for 
individuals who are not amenable to surgery. 
 
Stage IV: 
Stage IV colon tumors are those that have metastasized to various local or distant organs and 
tissues. The liver is one of the most common sites for metastasis in colon cancer. Other sites of 
metastatic disease include lungs, peritoneum, and distant lymph nodes. The majority of advanced 
colonic tumors are not amenable to surgery. In a few cases, however, surgery is still performed in 
order to prevent or manage complications. These surgeries may be colectomies, redirecting 
colostomies, or de-bulking procedures. In addition, radiotherapy and palliative chemotherapy may 
be implemented for stage IV disease if the need arises. Metastasectomy may be done for solitary, 
resectable liver or lung metastasis (80–84). 
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Fluorouracil has been the cornerstone of colorectal medical treatment for nearly 40 years. 
Following this, an increased disease-free and overall survival in stage III colon cancer were seen 
when a combination of fluorouracil and levamisole was administered. Subsequently, many studies 
have shown that the combination of fluorouracil with folinic acid has a similar benefit to 
fluorouracil with levamisole, with less toxicity. Further fluorouracil and folinic acid are 
administered for a period of six months, as opposed to fluorouracil and levamisole combination 
which is given for a year. The fluorouracil and folinic acid has been shown to increase the five-
year survival rate by an average of 5-10%, which represents a 25-35% reduction in mortality, and 
has now become a part of the standard treatment protocol. 
For stage II disease, the role of adjuvant chemotherapy has been inconsistent and chemotherapy is 
administered depending on other parameters like tumor size, depth of tumor, tumor differentiation 
and lymphovascular invasion. (78)  
 Irinotecan and oxaliplatin are two newer drugs which are in phase III trials and have been to report 
to double the chemotherapy response rate and increase the progression-free survival. Oxaliplatin 
has also proved to downsize liver metastases, hence enabling surgeons to perform a curative 
resection in patients whose tumor was previously considered inoperable. Bevacizumab, an anti-
VEGF (vascular endothelial growth factor) monoclonal antibody has recently been licensed for the 
first-line treatment of metastatic colon cancer by the US Food and Drug Administration. 
Cetuximab, a new antibody to the epidermal growth factor receptor (EGFR) is an upcoming 
chemotherapeutic agent for colorectal cancer. (78). 
The monoclonal antibodies have an immunomodulatory activity which acts through the host’s 
immune system to fight against the tumor cells. When immunotherapy is administered along with 
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conventional chemotherapy, there is a synergistic effect on cancer cells, inducing tumor cell death, 
eliminating regulatory T cells, and enhancing tumor cell sensitivity to lysis by cytotoxic T 
lymphocytes. These therapies are still under phase III trials(78,79).  
 
JUSTIFICATION FOR THIS STUDY 
 
               Colorectal cancer is one of the leading cause for mortality and morbidity worldwide and 
also in the Indian subcontinent and the rate of incidence is on the higher side, especially in young 
adults. Early detection and treatment have a major role in overall survival and disease-free survival 
rates. There are many prognostic factors and genetic biomarkers in order to assess the course of the 
disease. Recent studies show that CDX2 biomarker negative tumors had a bad histological 
prognostic factor and also a worse survival outcome. There are a few studies on CDX2 biomarker 
expression in association with a prognosis of colorectal cancer and yet another study has shown 
that stage2 CDX2 negative tumors had benefitted from adjuvant therapy. Hence, this study aims to 
assess clinical and histopathological features of colonic malignancy and to analyze the 
immunohistochemical expression of CDX2 and correlate the latter with histological factors of 
prognostic importance like the stage, grade of the tumor, lymphovascular invasion and lymph node 
status in the resection specimens of colonic adenocarcinoma in a tertiary care referral hospital. 
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STUDY SETTING 
This study was conducted in the department of General pathology on 148 consecutive mucosal 
biopsies with sufficient tumor and corresponding resection specimens of colonic adenocarcinoma 
diagnosed from January 1, 2015, to June 30, 2018. The clinicopathological details were retrieved 
from the electronic database and were reviewed systematically. The hematoxylin and eosin stained 
slides were reviewed for classification, grading, and staging. Immunostaining for CDX 2 was 
performed on freshly cut sections. The positive staining was graded for intensity and percentage of 
positive tumor cells. CDX 2 expression of the tumor cells were correlated with age, gender, 
clinical features, anatomical site, classification, grading and staging of the tumor including 
metastasis. 
 
RESEARCH BUDGET PLAN 
Institutional review board (IRB) Minutes number: 10624 approved our study. Interdepartmental 
collaboration between General Pathology and General Surgery significantly improved the quality 
of our research. The institutional Fluid Research grant account number (22 Z 294) was used to 
cover the costs of immunohistochemical staining. 
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SAMPLE SIZE 
The aim of the study is to know the prevalence of CDX 2 expression in colonic adenocarcinoma by 
immunohistochemistry and to correlate the expression CDX 2 with the clinicopathological 
parameters including stage and grade of colon cancer. Patients who had consecutive mucosal 
biopsies with sufficient tumor and corresponding resected specimens of colonic adenocarcinoma 
diagnosed in our hospital from January 1, 2015, to June 30, 2018, were recruited into our study. 
Preliminary analysis showed that the sample size required was 144 cases to meet the objectives of 
the study. 
INCLUSION CRITERIA 
All patients diagnosed as primary adenocarcinoma of the colon from January 1, 2015, to June 30, 
2018, on endoscopic mucosal biopsies and had resection following that performed in our 
institution.  
EXCLUSION CRITERIA 
1) Patients who had undergone biopsy for recurrent tumors. 
2) Patients with secondary metastatic disease to the colon. 
3) Primary colon malignancy diagnosed on endoscopic biopsy and did not have a resection 
following a diagnostic biopsy. 
4) Inadequate tissue for immunohistochemistry. 
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DATA SOURCES/MEASUREMENT 
The clinical details of the patients were obtained from the charts retrieved from the Medical 
Records Department and from the electronic database.  
QUANTITATIVE VARIABLES 
The variables analyzed in this study are listed in the proforma (see Annexure 1). 
Immunohistochemical marker were graded according to the score provided in the literature review. 
STATISTICAL ANALYSIS 
All study data was analyzed at first for descriptive statistics relating to demography and 
prevalence. Pearson’s Chi-square test was used to assess associations, using the SPSS software, 
where a P value of <0.05 was considered statistically significant 
METHODOLOGY 
This study utilized 148 matched mucosal biopsies and the corresponding surgical resections of the 
patients who were diagnosed with colonic adenocarcinoma in the Department of Pathology from 
January 1, 2015, to June 30, 2018. The slides and blocks of these cases were retrieved from the 
Archives. CDX2 immunohistochemistry (clone DAK-CDX2) using Detection Kits, in combination 
with a VENTANA automated slide stainer Benchmark XT, reduced the possibility of human error 
and inherent variability resulting from manual pipetting and manual reagent application. The 
technical procedure as described in Appendix-1. 
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                     RESULT 
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A total of 214 cases were included which were mucosal biopsy proven resection specimen reported 
as adenocarcinoma colon from January 2015 to June 2018. The archived slides and blocks were 
retrieved from the pathology records, Department of General Pathology. Of these cases, 148 cases 
were included in the study according to the inclusion and exclusion criteria. Thirty-three cases 
were eliminated as the mucosal biopsies were slides and blocks from elsewhere, seven cases had 
slides for mucosal biopsy but did not have a block and two cases had very scanty tumor, difficult to 
evaluate in mucosal biopsy while taking further sections for immunohistochemistry. One of the 
cases of adenocarcinoma colon was eliminated according to exclusion criteria since it was 
metastatic disease. Twenty-three cases were not included because of lack of block for further 
immunohistochemical examination.  The clinicomorphological and immunohistochemical features 
were analyzed for all 148 cases.  
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                                             214 cases 
                                                                                           33 cases – Slide & block review 
                                                                                             7 cases – Slide review 
                                                                                           23 cases – No block 
                                                                                            1 case – Metastatic disease to colon 
                                                                                              2 cases – No tumor in block 
                                            148 cases (Study group) 
 
 
 
 
Well                                   Moderately                    Poorly                      Mucinous 
differentiated                    differentiated                differentiated             carcinoma 
    (5)                                         (111)                           (16)                            (16) 
 
 
 
 
 
                                   CDX2 immunohistochemistry done 
 
 
 
         0 (no signal)   12                                                                    Intensity 
         1+ (<25%)      12                                                                    Mild 15  
         2+ (26-75%)   16                                                                 Moderate 26   
         3+ (>75%)     108                                                                  Strong 95 
                                           
 Fig 35: Selection of cases included under study 
 
 
c c 
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AGE  
The median age at diagnosis for all cases of colonic adenocarcinoma was 53 years (26-88 years) 
with a standard deviation of 12.33. The youngest patient was 26 years and the oldest patient was 88 
years old (Fig 9).  
                                                            Table 1: Age distribution in colon cancer 
  AGE (IN YEARS) NUMBER OF CASES 
(n=148) 
        <20                   0 
        21-30                   1 
        31-40                  17 
        41-50                  48 
        51-60                  34 
        61-70                  37 
        71-80                    7 
          >80      4 
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         Figure 9: Graphical representation of age distribution in colon cancer 
  
GENDER 
Of the 148 cases, 106cases were males, 42 were females. The distribution of cases showed a male 
preponderance. (Fig.10) 
 
                                      Figure 10: Gender distribution in colon cancer 
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CLINICAL FEATURES 
Most of the patients presented with abdominal pain as a major symptom (27%). The rest of the 
patients presented with constitutional symptoms like loss of appetite and weight, altered bowel 
habits, bleeding per rectum and anemia. A minority of patient presented with perforation peritonitis 
and obstruction. (Table 2) 
Table 2: Clinical presentations of Colon cancer 
CLINICAL PRESENTATION  NUMBER OF PATIENTS (n=148) 
Abdominal pain                         40 
Loss of appetite & weight                        28 
Altered bowel habit                        27 
Bleeding per rectum                        26 
Anemia                        15 
Tenesmus                          7 
Abdominal mass                          3 
Perforation peritonitis                          1 
Intestinal obstruction                          1 
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Figure 11: Graphical representation of the clinical presentation of Colon cancer 
 
 
SITE  
The most common site involved was the ascending colon (48), followed by sigmoid colon (43).  
The least involved site was descending colon. Hence, in this study the right sided colon cancer was 
found to be more when compared to left side colon cancers. 
. 
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Table 3: Anatomical sites of colon cancer 
                  SITE NUMBER OF PATIENTS (n=148) 
              CAECUM                 33 
        ASCENDING COLON                 48 
        TRANSVERSE COLON                 17 
        DESCENDING COLON                 7 
        SIGMOID COLON                 43 
 
 
Figure 12: Graphical representation of anatomical sites of colon cancer 
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TUMOR SIZE 
The tumor size ranges from 1cm to 13cm in maximum dimension with a median of 5.5cm and 
standard deviation of 2.25.  
 
TUMOR GROSS MORPHOLOGY. 
Ulceroproliferative tumors (104) are the most common gross morphology out of the other five 
types encountered in this study. The least one is annular, constrictive type (5). 
 
Table 4: Gross morphology of colon cancer 
       GROSS MORPHOLOGY  NUMBER OF PATIENTS (n=148) 
Ulceroproliferative                   104 
Polypoid                     26 
Ulcerative                     13 
Annular constriction                       5 
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TUMOR HISTOLOGY 
The 148 cases were classified into one of the following histological types according to the WHO - 
Well differentiated, moderately differentiated, poorly differentiated and mucinous carcinoma. 
Majority of the tumor were classified as moderately differentiated adenocarcinoma (111 in 
number). The poorly differentiated and mucinous carcinoma had 16 cases each. 
 
 
Table 5: Histological subtypes of colon cancer 
                 HISTOLOGY NUMBER OF PATIENTS (n=148) 
   Well-differentiated adenocarcinoma                            5 
   Moderately differentiated adenocarcinoma                         111 
  Poorly differentiated adenocarcinoma                           16 
  Mucinous carcinoma                           16 
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Figure 13: Graphical representation of the histological subtypes of colon cancer. 
 
PATHOLOGICAL STAGING 
PRIMARY TUMOR 
Primary tumor invasion depends on the depth of tumor infiltration. pT3 constituted about 59% of 
total cases, followed by T4a (22%) and pT1 (1%) had the least cases. 
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Table 6: Primary tumor invasion 
PRIMARY TUMOUR INVASION     PERCENTAGE OF CASES 
           pT1                   1 
           pT2                  11  
           pT3                  59 
           pT4a                  22 
           pT4b                   7 
 
 
 
 
Figure 14: Graphical representation of primary tumor invasion. 
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REGIONAL LYMPH NODES 
Most of the tumor did not have regional lymph node metastasis (52%). Among the remaining 
lymph node metastasis cases, pN1b (2-3 regional lymph node metastasis) comprises 18% of cases. 
Table 7: Regional lymph node metastasis. 
 REGIONAL LYMPH NODES METASTASIS   PERCENTAGE OF CASES   
                       pN0                  52 
                       pN1a                  14 
                       pN1b                  18 
                       pN1c                   8 
                       pN2a                  12 
                       pN2b                    5 
 
 
 
Figure 15: Graphical representation of regional lymph node metastasis 
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METASTASIS 
Out of 148 cases, 12 cases had distant organ metastasis. Nine out of twelve cases have liver 
metastasis (75%) and remaining three cases have lung metastasis (25%). 
 
                                        Figure 16: Metastatic colon cancer site distribution 
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STAGE  
The majority of cases with colon cancer were in Stage II and in Stage III status. Only 12 cases were 
found to have Stage IV disease in which metastasis was to liver and lung. 
                  Table 8: Stage of colon cancer 
   
         
 
 
           Figure 17: Graphical representation of the stage of colon cancer 
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66 
 
 
 
LYMPHOVASCULAR AND PERINEURAL INVASION 
On histological examination, only fifty percentages of cases had a lymphovascular invasion. But 
the major proportion of cases do not have perineural invasion (83%). Rest 17% of the cases show 
perineural invasion. 
 
MARGINS 
Proximal and distal margins were not involved in 148 cases. 
 
IMMUNOHISTOCHEMISTRY 
CDX2 immunohistochemistry was negative in 12 cases out of 148 tumor cases (8%). Remaining 
136 cases (92%) showed positivity for CDX2 immunohistochemistry but varied in cell proportion 
and intensity. CDX2 biomarker positive cases were subcategorized into 1+ (<25%), 2+ (26-75%) & 
3+ (>76%) according to percentage of positive cells. The intensity of CDX2 positive also varied 
from mild, moderate and strong. Majority of tumor cases were 3+ (73%) and strong intensity 
(70%).   
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Table 9: Distribution of colon cancer by the percentage of positive cells. 
GRADING ON % CDX2 POSITIVE CELLS         PERCENTAGE OF CASES N=148) 
                           0   8% 
                     1+ (<25%)  8% 
 2+ (26-75%)  11% 
                           3+ (>75%)                            73% 
 
 
Table 10: Distribution of colon cancer by the intensity of positive cells. 
  INTENSITY OF CDX2 POSITIVITY         PERCENTAGE OF CASES (N=136) 
 MILD    11% 
                        MODERATE   19% 
  STRONG      70% 
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Figure 18: Graphical representation of colon cancer by the percentage of positive cells. 
 
Figure 19: Graphical representation of colon cancer by the intensity of positive cells. 
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CDX 2 IMMUNOHISTOCHEMISTRY STUDY 
CDX2 AND DEMOGRAPHY 
On immunohistochemical analysis, CDX2 was positive in 136 cases and negative for 12 cases. In 
our study, CDX2 immunohistochemistry negativity was compared with demographic and 
histopathological features. The CDX2 expression was found to be negative more often in men than 
in women, however, the number of men with colon cancer was proportionately higher than in 
women in our study. There were no statistical significances found between CDX2 expression with 
patient’s age, gender and clinical features in our study.  
CDX2 AND TUMOUR MORPHOLOGY 
Tumor location, size, and gross appearances were also compared with CDX2 
immunohistochemistry expression. Most of the CDX2 negative tumors were located in the sigmoid 
colon (41.67%) and were of the ulceroproliferative morphology (91.67%) grossly. All these 
parameters were found to be statistically insignificant. CDX2 negativity was observed mostly in 
poorly differentiated adenocarcinoma (12.5%) and mucinous carcinoma (12.5%) when compared 
with moderately differentiated adenocarcinoma (7.2%). When the depth of tumor invasion was 
assessed, the majority of the cases of CDX2 immunohistochemistry were found to be negative in 
pT3 (41.67%), and pT4b (25%) stages.  Among the cases with regional lymph node metastasis, 
CDX2 immunohistochemistry negativity was noted to be slightly higher in pN2a and pN2b (25% 
each) cases when compared to pN0 (8.33%) though it was not statistically significant.  
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CDX2 AND TUMOUR METASTASIS 
Though eight out of twelve cases with lymphovascular invasion (66.67%) were negative for CDX2 
immunohistochemistry, there was no statistical significance noted. Similarly, ten out of twelve 
cases with perineural invasion (83.33%) were negative for CDX2 immunohistochemistry which 
was not statistically significant. Among tumors with liver metastasis, 28.6% of cases were CDX2 
negative and among tumors with lung metastasis, 66.7% of cases were CDX2 negative but had no 
statistical significance. 
Table 11: Association between CDX2 status and clinical parameters 
                                         Total cases              CDX2 positive        CDX2 negative             P value 
                                        n=148(100%)            136 (92%)                  12(8%)                (Significant<0.05) 
Age                                                                                                         0.532 
<40                                      18(12.16)                17(12.5)                   1(8.34)          
>40                                    130(87.83)              119(87.5)               11(91.66) 
Gender 0.348 
Male  106(71.62)                96(70.59)               10(83.33) 
Female    42(28.38)                40(29.41)                2(16.67)                      
Clinical features 
Abdominal pain                   91(61.49)                 85(62.5)                     6(50)                           0.394 
LOW & LOA                      66(44.59)               59(43.38)                  7(58.33)                         0.318 
Bleeding PR                         64(43.24)              59(43.38)                  5(41.67)                         0.908   
Altered bowel habit             62(41.89)               58(42.65)                  4(33.33)                         0.531 
Anemia                                35(23.65)               31(22.79)                  4(33.33)                         0.410 
Tenesmus                               12(8.11)                10(7.35)                   2(16.67)                         0.257 
Abdominal mass                      8(5.41)                  7(5.15)                     1(8.33)                         0.640 
Perforation                               2(1.35)                2(16.67)                      0 
Intestinal obstruction               1(0.68)                  1(0.74)                      0 
LOW loss of weight, LOA loss of appetite, PR per rectum 
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Table 12: Association between CDX2 status with tumor  
                                Number of cases                  CDX2 positive          CDX2 negative             P value 
                                   n=148(100%)                    136 (92%)                 12(8%)                 (Significant<0.05) 
Tumor size                                                                                                                               0.324 
<6.5cm                          103(69.59)                           93(68.38)            10(83.33)                
>6.5cm                            45(30.41)                           43(31.62)             2(16.67) 
 
Tumor location 
Caecum                            33(22.3)                           31(22.79)              2(16.67)                       0.625 
Ascending colon            48(32.43)                           45(33.09)                3(25)                          0.566 
Transverse colon           17(11.49)                            16(11.77)               1(8.33)                       0.434 
Descending colon             7(4.73)                                 6(4.41)               1(8.33)                       0.540 
Sigmoid colon               43(29.05)                            38(27.94)             5(41.67)                       0.315 
 
Tumor pattern                                                                                                                             NA 
Polypoid                        26(17.57)                           26(19.12)                     0 
Ulcerative                        13(8.78)                             13(9.56)                     0 
Ulceroproliferative      104(70.27)                           93(68.38)            11(91.67) 
Annular                              5(3.38)                               4(2.94)               1(8.33) 
 
Tumor histology                                                                                                                           NA 
Well differentiated             5(3.38)                              5(3.68)                      0           
Moderately differentiated  111(75)                        103(75.74)              8(66.67) 
Poorly differentiated       16(10.81)                          14(10.29)             2(16.67) 
Mucinous carcinoma       16(10.81)                         14(10.29)              2(16.67) 
 
Tumor invasion                                                                                                                             NA 
pT1                                     2(1.35)                              2(1.47)                      0 
pT2                                 17(11.49)                           15(11.03)              2(16.67) 
pT3                                 87(58.78)                           82(60.29)              5(41.67)  
pT4a                                32(21.62)                          30(22.06)               2(16.67)    
pT4b                                  10(6.76)                            7(5.15)                3(25) 
 
Lymph node metastasis                                                                                                                NA 
pN0                                77(52.03)                          76(55.88)                1(8.33) 
pN1a                              20(13.51)                          18(13.24)              2(16.67) 
pN1b                              26(17.57)                          25(18.38)                1(8.33) 
pN1c                                  8(5.41)                             6(4.41)               2(16.67) 
pN2a                                12(8.11)                             9(6.62)                   3(25) 
pN2b                                 5(3.38)                              2(1.47)                   3(25) 
NA – Not applicable 
72 
 
Table 13: Association between CDX2 status with tumor stage 
                                              Number of cases       CDX2 positive       CDX2 negative             P value 
                                                 n=148(100%)           136 (92%)                  12(8%)           (Significant<0.05)  
                           0.425 
   STAGE     I                14(9.46)                 12(8.82)                  2 (16.67)       
   STAGE    II                              62(41.89)               59(43.38)                3(25) 
  STAGE     III                             60(40.54)               55(40.44)                5 (41.67) 
  STAGE     IV                             12(.8.11)                10(7.35)                  2(16.67) 
          
  Table 14: Association between CDX2 status with tumor invasion 
                                              Number of cases       CDX2 positive       CDX2 negative             P value 
                                                 n=148(100%)           136 (92%)                  12(8%)           (Significant<0.05)  
Lymphovascular invasion             74(50)                   66(48.53)                8(66.67)                 0.228 
Perineural invasion                   25(16.89)                  15(11.02)               10(83.33)                0.409 
 
 
Table 15: Association between CDX2 status with tumor metastasis 
                                              Number of cases       CDX2 positive       CDX2 negative             P value 
                                                   n=12(100%)            8(83%)                    4(17%)         (Significant<0.05)  
Metastasis                                                                                                                                 0.371 
Liver                                              9(75)                    7(87.5)                     2(50)                 
Lung                                              3(25)                    1(12.5)                     2(50)                                                      
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                             Figure 20: CDX2 immunohistochemistry positive control (10X magnification) 
 
 
                         
                                       Figure 21: CDX2 immunohistochemistry negative tumor 
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                         Figure 22: CDX2 immunohistochemistry positive tumor with mild intensity 
 
 
                       
                         Figure 23: CDX2 immunohistochemistry positive tumor with moderate intensity 
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                              Figure 24: CDX2 immunohistochemistry positive tumor with strong intensity 
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              DISCUSSION 
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In our study, CDX 2 immunohistochemistry was correlated with clinicopathological features, 
including grading and staging of colonic adenocarcinoma. 148 cases of colonic adenocarcinoma 
were included from January 2015 till the end of June 2018. 
 
AGE  
 
Globally, the incidence of CRC is higher in the population ≥65 years of age (1). In our study, the 
median age of diagnosis was 53 years with the youngest patient of 26 years. This was in keeping 
with the Indian studies published earlier, for example, a study by Patil PS et al, in which the mean 
age at diagnosis was 47 years (2). This was in contrast with many of the published western studies 
(1, 3-5). The incidence of colon cancer among the young in India may be due to a large proportion 
of the young population with a broad-based population pyramid (2). Change in lifestyle and 
environmental factors may also play an important role in this shift of trend. There is no significant 
association eluted when age was compared with CDX2 immunohistochemistry expression in this 
study.  
 
GENDER 
 
In our study, there was a male preponderance (70.59%) which was in concordance with many 
western and Indian studies (1-5). However, there was no statistical correlation between CDX2 
immunohistochemistry expression and gender found in this study.  
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CLINICAL FEATURES 
 
The most common symptom was abdominal pain (61.49%) in our study which was not in line with 
other Indian and western studies which project bleeding per rectum as the commonest 
symptoms(2). The logical explanation for this disparity could be due to a higher number of right-
sided colon cancer found in our study than the left-sided ones which usually present as bleeding 
per rectum. The CDX2 immunohistochemistry expression was not found to be statistically 
significant with any of the symptoms of colon cancer. 
 
TUMOR PATHOLOGY 
 
In our observation, right-sided colon cancer, predominantly involving ascending colon cancer, was 
found to be significantly more prevalent compared to the left-sided colon cancers as published in 
the western literature (83, 84). This is in contrast to the Indian studies in which left-sided colon 
cancers were found to be more common. This could be partly explained by the fact that screening 
sigmoidoscopies would have mainly targeted precursor lesions in the left colon which are easily 
accessible. Poor preparations and incomplete evaluations during colonoscopy would have had a 
bigger impact on right-sided tumors. The third reason could be due to the inclusion of rectal cancer 
along with colonic cancers in the Indian studies. Conventional moderately differentiated 
adenocarcinoma formed the major proportion of tumors in our study because of increased 
incidence of colonic adenocarcinoma among the older age group, unlike the studies by Patil PS et 
al (2) and Patra et al (87) in which signet ring cell carcinomas and mucinous adenocarcinoma 
formed significantly greater proportion respectively in the younger population. Most of the CDX2 
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immunohistochemistry negative tumors were poorly differentiated adenocarcinoma and mucinous 
carcinoma, pT3 (41.67%) and pT4 (41.67%). Fifty percentage of CDX2 negative tumors were of 
the pN2 stage (88–91). Hence, our study revealed a direct correlation between CDX2 
immunohistochemistry negativity and depth of tumor invasion, lymph node metastasis, and tumor 
grading, although it was not statistically significant. 
 
TUMOR METASTASIS 
 
In our study, the percentage of cases which had metastasis was approximately 8.1% which may be 
due to prompt screening and early diagnosis of cancer. Among metastasis, the commonest site was 
found to be liver (75%) which was congruent with previous studies (2, 88). CDX2 negative status 
was common in cancers with liver and lung metastasis but had no statistical significance with 
CDX2 immunohistochemistry negativity. 
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• Colon cancer cases had a median age of 53 years with a male preponderance. 
• The most common site of occurrence of colon cancer was right-sided colon (ascending 
colon). 
• The most common clinical presentation was abdominal pain followed by loss of appetite, 
altered bowel habit and bleeding per rectum. 
• The prevalence of CDX2 expression in colon cancer in our population was found to be 8%. 
• CDX2 immunohistochemistry negativity was found to be increased in patients above 40 
years of age, in males, in left-sided colon cancers and in poorly differentiated 
adenocarcinoma and mucinous carcinoma, though these associations were not statistically 
significant. 
• CDX2 negative status was more common among tumors with higher pathological TNM 
stage and those with liver and lung metastasis. 
• The liver was found to be the commonest site for metastatic colon cancer though it had no 
significant statistical correlation with CDX2 immunohistochemical expression. 
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              LIMITATION 
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Since the incidence of poorly differentiated adenocarcinoma, mucinous carcinoma, and signet ring 
carcinoma was low compared to the moderately differentiated adenocarcinoma in our study, it was 
difficult to correlate CDX2 immunohistochemical negativity with tumor grade and to prove the 
aggressive behavior of CDX2 negative tumors. 
  
 The CDX2 expression could be affected due to intratumoral heterogeneity, according to an Indian 
study, which reported a lower expression in the invasive front of the tumor compared to the tumor 
center. Hence an accurate evaluation of the CDX2 expression may not have been possible in small 
endoscopic mucosal biopsies. Multiple site mucosal biopsies would have been ideal for proper 
assessment of CDX 2 expression.  
 
The prognosis of colon cancer was not compared with CDX2 immunohistochemistry expression in 
our study since CDX2 has been proven to be an independent prognostic factor, irrespective of 
tumor grade and stage in many of the studies. Therefore, the relevance of CDX2 
immunohistochemistry negativity would be clearer when compared with survival and mortality.  
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APPENDIX 1 - Protocol for automated immunostaining:  
1. Paraffin-embedded tissue sections were cut at the 4μ thickness and floated in poly L lysine 
coated slides incubated overnight at 37degree Celsius.  
2. These slides were then treated with 4% milk solution for 10 minutes to eliminate the 
hydrophobic effect and give a positive charge to the slides.  
3. Then the slide labels were barcoded and the labeled slides were loaded in Ventana Benchmark 
XT autostainer (a fully automated autostainer).  
4. Individual protocols have been devised in the software attached to the machine for each marker. 
Specific protocols were selected according to the marker.  
5. A standard protocol was used for most of the markers with minimal variation for few individual 
markers. The steps included in the protocol were as follows.  
a) Deparaffinisation  
b) Liquid coverslip application  
c) Heat-induced antigen retrieval by treating with a standard CC1 solution (pH patent for the 
company) for one hour at 90 degree Celsius.  
6. Then the primary antibody was added and incubated for 40 min at 37 degree Celsius.  
7. Then the secondary antibody was added and incubated for 8 minutes.  
8. Finally, the slides were counterstained with hematoxylin and incubated for 8 min, followed by 
incubation with the bluing agent for 4 min.  
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9. From antigen retrieval till counterstaining, in between every step, the slides were washed with 
reaction buffer. The whole processing is automated. Then the slides were brought to 80% alcohol 
(2 changes) to remove the liquid coverslip and then dried and mounted in DPX.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
ANTIBODY  CLONE  DILUTION  SOURCE  
MONOCLONAL MOUSE 
ANTI-HUMAN CDX 2 
DAK-CDX2 
Std 40 
    1:75 DAKO 
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APPENDIX 2 - Proforma 
A study of the clinicopathological profile and prevalence of CDX2 biomarker expression in 
primary adenocarcinoma of colon in a tertiary care hospital among Indian population 
 
1. ID NO-            2. AGE        3. SEX       4. MUCOSAL BIOPSY NO:                5.RESECTION BIOPSY NO: 
5. CLINICAL FEATURES: 
       BLEEDING PER RECTUM       Y/N                    LOSS OF WEIGHT & APPETITE Y/N  
       ABDOMINAL PAIN                  Y/N                    TENESMUS                                   Y/N 
       ANAEMIA                                 Y/N                    ALTERED BOWEL HABITS           Y/N 
      ABDOMINAL MASS                 Y/N                     INTESTINAL OBSTRUCTION      Y/N 
      PERFORATION                          Y/N 
6. PAST HISTORY 
   a) ANY OTHER MALIGNANCIES:                                   
   b) ANY MALIGNANCIES IN FAMILY: 
 
7.  MACROSCOPIC FINDINGS 
7.1 ANATOMICAL SITE 
a) CAECUM                                    Y/N               e) SPLENIC FLEXURE                   Y/N 
b) ASCENDING COLON                Y/N               f) DESCENDING COLON              Y/N 
c) HEPATIC FLEXURE                    Y/N               g) SIGMOID COLON                    Y/N 
d) TRANSVERSE COLON              Y/N 
 
7.2 GREATEST TUMOUR DIMENSION:       cm 
 
7.3 PATTERN OF GROWTH:   a) POLYPOIDAL        b) ULCERATIVE        c) ULCEROPROLIFERATIVE  
                                                    f) ANNULAR/ CONSTRICTION                  e) DIFFUSE                                                     
 
8. MICROSCOPIC FINDINGS 
8.1 HISTOLOGICAL TUMOUR DIFFERENTIATION 
a) GRADE1 WELL DIFFERENTIATED (>95% OF TUMOUR COMPOSED OF GLANDS)                        
b)  GRADE 2 MODERATELY DIFFERENTIATED (50-95% OF TUMOUR COMPOSED OF GLANDS)   
c)  GRADE3 POORLY DIFFERENTIATED (<50% OF TUMOUR COMPOSED OF GLANDS)                   
d) SIGNET RING CELL CARCINOMA                                                                                                          
e) MUCINOUS CARCINOMA                                                                                                                      
f) OTHERS: 
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8.2 TUMOR INVASION 
a)  pT0: No evidence of primary tumor                                                                                
b)  pTis: Carcinoma in situ, intraepithelial (no invasion of lamina propria)                   
c)  pTis: Carcinoma in situ, invasion of lamina propria/muscularis mucosae                
d)  pT1: Tumor invades submucosa                                                                                      
e)  pT2: Tumor invades muscularis propria                                                                         
f)   pT3: Tumor invades through the muscularis propria into pericolorectal tissues   
g)  pT4a: Tumor penetrates the visceral peritoneum                                                        
h)  pT4b: Tumor directly invades or is adherent to other organs or structures            
8.3 REGIONAL LYMPH NODES  
 a) pN0: No regional lymph node metastasis                                                                
 b) pN1a: Metastasis in 1 regional lymph node                                                            
 c) pN1b: Metastasis in 2 to 3 regional lymph nodes                                                   
d)  pN1c: Tumor deposit(s) in the subserosa, or pericolic or perirectal tissues      
                  without regional lymph node metastasis 
 e) pN2a: Metastasis in 4 to 6 regional lymph nodes                                                   
 f) pN2b: Metastasis in 7 or more regional lymph nodes                                            
8.4 LYMPHOVASCULAR INVASION      Y/N                     
8.5 PERINEURAL INVASION    Y/N 
8.6 MARGINS INVOLVED    - a. PROXIMAL   Y/N                 b. DISTAL    Y/N 
8.7 DISTANT METASTASIS    Y/N   IF YES, SITE- ……. 
9 CDX2 IMMUNOHISTOCHEMISTRY  
9.1 PERCENTAGE OF POSITIVE CELLS: 
  a)  0 (NO SIGNAL)                  c) 2+ (26-75%)                 
  b)  1+ (<25%)                         d) 3+ (>75%)                  
9.2 INTENSITY OF POSITIVE CELLS 
  a) MILD               
  b) MODERATE    
  c) STRONG          
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